ZFYVE16

Across TCGA pan-cancer cohorts, ZFYVE16 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZFYVE16 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ZFYVE16 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZFYVE16 expression acts as an unfavorable survival marker, although some lineages such as LSCC and OV show a favorable association.

GBM, LSCC, and OV are the cancer types where ZFYVE16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.283	0.700	.005	10	view →
LSCC	OS	Median	II,III,IV	0.943	0.784	.014	7	view →
OV	DFS	Median	All	1.000	0.707	.041	4	view →
LUAD	OS	Tertile	III,IV	0.849	0.438	.019	4	view →
PDAC	OS	Median	IV	0.911	0.540	.049	3	view →
HNSC	OS	Quartile	IV	0.856	0.567	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZFYVE16–GBM (OS)

Open the GBM breakdown →